{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:19:59Z","timestamp":1776356399864,"version":"3.51.2"},"reference-count":78,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the COMPETE 2020 Operational Program for Competitiveness and Internationalization (POCI), Portugal 2020"},{"name":"Portuguese funds through Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)"},{"name":"CHAIR in Onco-Innovation from the Faculty of Medicine, University of Porto (FMUP)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Lung cancer is the most lethal malignancy worldwide, having the highest incidence rate. This is a heterogeneous disease classified according to its histological and molecular characteristics. Depending on these, different therapeutic approaches have already been approved for lung cancer treatment targeting genetic alterations or even the immune system. Nonetheless, other therapies are being studied to continuously improve the care and survival of lung cancer patients. Among them, immunotherapies are one of the main targets of investigation to try and combat the ability of some malignant cells to evade anti-tumor responses mediated by the immune system. Cancer vaccine development has emerged as a promising approach to strengthen the patient\u2019s immune system and combat the disease, especially mRNA vaccines. Currently, there are several ongoing studies investigating the therapeutic efficacy of mRNA vaccines in lung cancer treatment alone or combined with other therapeutic drugs. This review aims to highlight the importance of immunotherapy in lung cancer treatment, presenting the most recent advances particularly in mRNA-based vaccines as well as the challenges and future perspectives.<\/jats:p>","DOI":"10.3390\/vaccines13050476","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:00:39Z","timestamp":1745917239000},"page":"476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging Immunotherapies in Lung Cancer: The Latest Advances and the Future of mRNA Vaccines"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5324-8826","authenticated-orcid":false,"given":"Raquel","family":"Ramos","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer Progress and Priorities: Lung Cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/0141076819843654","article-title":"Lung cancer in never-smokers: A hidden disease","volume":"112","author":"Bhopal","year":"2019","journal-title":"J. R. Soc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41588-021-00920-0","article-title":"Genomic and evolutionary classification of lung cancer in never smokers","volume":"53","author":"Zhang","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e001021","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: Results of a nationwide registry study","volume":"5","author":"Provencio","year":"2020","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3322\/caac.21811","article-title":"Screening for lung cancer: 2023 guideline update from the American Cancer Society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13244-024-01814-5","article-title":"Strengthening lung cancer screening in Europe: Fostering participation, improving outcomes, and addressing health inequalities through collaborative initiatives in the SOLACE consortium","volume":"15","author":"Kauczor","year":"2024","journal-title":"Insights Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational Implications of Tumor Heterogeneity","volume":"21","author":"Quezada","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications","volume":"16","author":"Marino","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: Progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mamdani, H., Matosevic, S., Khalid, A.B., Durm, G., and Jalal, S.I. (2022). Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.823618"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ramos, R., Moura, C.S., Costa, M., Lamas, N.J., Correia, R., Garcez, D., Pereira, J.M., Sousa, C., and Vale, N. (2024). Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes. J. Pers. Med., 14.","DOI":"10.3390\/jpm14050446"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00262-025-03958-9","article-title":"Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer","volume":"74","author":"Cheng","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11864-025-01292-x","article-title":"Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer","volume":"26","author":"Shen","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e009667","DOI":"10.1136\/jitc-2024-009667","article-title":"New developments in immunotherapy for SCLC","volume":"13","author":"Dolkar","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12432","article-title":"Dendritic cell maturation and cross-presentation: Timing matters!","volume":"272","author":"Alloatti","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/bs.ai.2020.10.002","article-title":"Unexplored horizons of cDC1 in immunity and tolerance","volume":"148","author":"Balan","year":"2020","journal-title":"Adv. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: Their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mundhara, N., and Sadhukhan, P. (2024). Cracking the Codes behind Cancer Cells\u2019 Immune Evasion. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168899"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","year":"2021","journal-title":"World J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhou, S., Liu, M., Ren, F., Meng, X., and Yu, J. (2021). The landscape of bispecific T cell engager in cancer treatment. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00294-9"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of Non-Small-Cell Lung Cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Caliendo, F., Dukhinova, M., and Siciliano, V. (2019). Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology. Front. Bioeng. Biotechnol., 7.","DOI":"10.3389\/fbioe.2019.00043"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CCO.0000000000000052","article-title":"Vaccination therapy for non-small-cell lung cancer","volume":"26","author":"Cuppens","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: Between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PPO.0b013e318233e6b4","article-title":"Lung Cancer Vaccines","volume":"17","author":"Kelly","year":"2011","journal-title":"Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox","volume":"367","author":"Moore","year":"2006","journal-title":"Lancet"},{"key":"ref_35","first-page":"287s","article-title":"A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771","volume":"106","author":"Gail","year":"1994","journal-title":"Chest"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/hv.19795","article-title":"Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer","volume":"8","author":"Gardner","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12032-024-02489-0","article-title":"Vaccine-based therapeutic interventions in lung cancer management: A recent perspective","volume":"41","author":"Gupta","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#","article-title":"Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer","volume":"55","author":"Hoover","year":"1985","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"Traversari","year":"1991","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2012.43.7103","article-title":"Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results","volume":"31","author":"Vansteenkiste","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Vishweshwaraiah, Y.L., and Dokholyan, N.V. (2022). mRNA vaccines for cancer immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1029069"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Guo, C., Manjili, M.H., Subjeck, J.R., Sarkar, D., Fisher, P.B., and Wang, X.-Y. (2013). Therapeutic Cancer Vaccines, Elsevier.","DOI":"10.1016\/B978-0-12-407190-2.00007-1"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14712598.2020.1815704","article-title":"Recent developments of RNA-based vaccines in cancer immunotherapy","volume":"21","author":"Faghfuri","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.4161\/onci.20926","article-title":"Overcoming HLA restriction in clinical trials","volume":"1","author":"Wilgenhof","year":"2012","journal-title":"OncoImmunology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"114142","DOI":"10.1016\/j.addr.2022.114142","article-title":"Toward rational vaccine engineering","volume":"183","author":"Vishweshwaraiah","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/1759-7714.14375","article-title":"CAR-T cell therapy for lung cancer: Potential and perspective","volume":"13","author":"Chen","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.2147\/OTT.S197516","article-title":"Irradiation increases the immunogenicity of lung cancer cells and irradiation-based tumor cell vaccine elicits tumor-specific T cell responses in vivo","volume":"12","author":"Luo","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial","volume":"22","author":"Ciuleanu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/ijc.35088","article-title":"The current therapeutic cancer vaccines landscape in non-small cell lung cancer","volume":"155","author":"Chen","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/mt.2015.138","article-title":"mRNA: Fulfilling the Promise of Gene Therapy","volume":"23","author":"Weissman","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.nanolett.9b03483","article-title":"Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination","volume":"20","author":"Son","year":"2020","journal-title":"Nano Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/82_2020_202","article-title":"Messenger RNA-Based Vaccines Against Infectious Diseases","volume":"440","author":"Alameh","year":"2022","journal-title":"Mrna Vaccines"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Anindita, J., Tanaka, H., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Oyama, T., Suzuki, S., Ueda, K., and Higashi, K. (2024). The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020181"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ramadan, E., Ahmed, A., and Naguib, Y.W. (2024). Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions. J. Pers. Med., 14.","DOI":"10.3390\/jpm14111092"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2307187","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"122652","DOI":"10.1016\/j.lfs.2024.122652","article-title":"Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances","volume":"346","author":"Sanaei","year":"2024","journal-title":"Life Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Kiousi, E., Lyraraki, V., Mardiki, G.L., Stachika, N., Damianou, A.K., Malainou, C.P., Syrigos, N., Gomatou, G., and Kotteas, E. (2023). Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC. Cancers, 15.","DOI":"10.3390\/cancers15235589"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1081\/CNV-120018224","article-title":"Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA","volume":"21","author":"Morse","year":"2003","journal-title":"Cancer Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"TPS9107","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9107","article-title":"Phase 1\/2 study of mRNA vaccine therapy + durvalumab (durva) \u00b1 tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"36","author":"Gandhi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S1095","DOI":"10.1016\/j.annonc.2022.07.1319","article-title":"1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer","volume":"33","author":"Forde","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-024-03678-z","article-title":"The progress of tumor vaccines clinical trials in non-small cell lung cancer","volume":"27","author":"Wang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhang, C., Li, Y., Tan, X., Li, W., Tan, S., and Liu, G. (2024). Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-53622-y"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:23:36Z","timestamp":1760030616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":78,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["vaccines13050476"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13050476","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}